B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
VNDA
VandaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.40
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-22
Recent news sentiment (30D)
-0.4
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.5
Score
AI commentary
The positive September HETLIOZ result was followed by the October 14 VQW-765 failure, a material deterioration from the prior speculative-buy thesis. Reuters reported shares down about 17% in extended trading immediately after the failure; the packet's later October 21 anchor is $4.01. Reuters. No verified post-print analyst revisions, options skew, short-interest, employee score, or sufficient social measure were available; zero-valued fields denote missing data, not neutral readings. The deterministic prior remains positive, but the failed trial and thin target coverage limit conviction.
RankAlpha Sentiment Codex - 2026-10-22
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-12eventQuimilza FDA decisionHigh impact
The FDA target action date for Quimilza in generalized pustular psoriasis is December 12, 2026. Approval, delay, or rejection could materially change the pipeline valuation. [#SEC-8K-2026-08-05] SEC-filed company release.
2026-12-31eventNEREUS GLP-1 vomiting trial readoutHigh impact
Vanda expected results from its Phase III NEREUS study in patients receiving GLP-1 therapies during 2026. The outcome remains unreported in the checked evidence; the date is a company-stated window, not a confirmed release date. [#SEC-8K-2026-08-05] SEC-filed company release.
2027-06-30catalystHETLIOZ supplemental-application pathHigh impact
Vanda reported a 37.1-minute placebo-adjusted improvement in sleep-onset timing in its Phase III delayed sleep-wake phase disorder study and intends to discuss the data with FDA and submit an sNDA. The analyzed primary-endpoint groups had 20 participants each; no filing date or approval is assured. [#PR-EARNINGS-2026-09-29].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-22 • Updated nightlySource: Internal modelMethodology